Founded in 2007 and headquartered in Gaithersburg, MD, Amplimmune is focused on developing novel therapeutics through immune system modulation. With its strong
product-based focus, Amplimmune has rapidly developed three biologic product candidates:
By leveraging its GMP manufacturing capabilities and in depth knowledge of immunomodulatory pathways, Amplimmune is developing novel immunomodulatory molecules
with broad spectrum applications in the treatment of cancer, autoimmunity, transplantation and infectious diseases. Working closely with key academic and industry
collaborators, Amplimmune has created a platform of novel reagents, models, know-how and intellectual property to further develop a unique product pipeline including
novel biomarkers, ligands and receptors.